- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Urothelial cancer Colorectal cancer Primary Mediastinal B-cell Lymphoma Classical Hodgkin Lymphoma
- Meeting Date: July 2022
- Public Summary Document (PSD) July 2022 PBAC Meeting - (PDF 799KB)
- Public Summary Document (PSD) July 2022 PBAC Meeting - (Word 167KB)
Pembrolizumab – July 2022
Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
28 October 2022